Bicarbonate plus chemo and immunotherapy for pancreatic cancer liver spread
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests adding sodium bicarbonate to a chemotherapy plus immunotherapy regimen for pancreatic cancer that has spread to the liver. The goal is to see if this combination helps shrink tumors and improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have pancreatic cancer that started in the pancreatic duct and has spread to the liver.
- You are well enough to be up and about (ECOG score 0-2).
- Your key blood counts, liver and kidney function tests are within acceptable ranges.
- You are at least 3 weeks past any recent cancer treatments and have recovered from side effects.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy (adebelimab) and chemotherapy drugs (irinotecan liposome, oxaliplatin, fluorouracil, and calcium folinate) as a first treatment for pancreatic cancer that has spread to the liver. The goal is to see if this combination is safe and effective.
This trial tests whether adding an immunotherapy drug (sintilimab) to standard chemotherapy before and after surgery helps shrink tumors and improve outcomes for people with pancreatic cancer that can be removed.
This trial tests a new drug (BMS-986340) plus standard chemo for people whose pancreatic cancer has spread or come back. The goal is to see if this combination works better.
This trial tests a new immunotherapy drug called ivonescimab combined with chemotherapy, with or without another experimental drug (AK117), for people with pancreatic cancer that has spread. The goal is to see if adding these therapies can help shrink tumors or slow the cancer's growth.
This trial tests a new combination of drugs (NC410 plus chemotherapy and nivolumab, with or without ipilimumab) for people with metastatic pancreatic cancer who haven't had treatment yet. The goal is to see if adding these immunotherapy agents can help shrink or control the tumor.
This trial tests a combination of chemotherapy (NALIRI-XELOX) plus a newer immunotherapy drug (AK104) as a first treatment for people with advanced pancreatic cancer that hasn't been treated yet. The goal is to see if this combination works better than standard treatments.
Hear when a new Pancreatic Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.